1. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques
- Author
-
Pranita Gawande, Sanjay Kumar, Rashmi Gunjikar, Deepak Mali, Rajlaxmi Jain, Priya Abraham, Raches Ella, Abhinendra Kumar, Manoj Kadam, Prasad Sarkale, Himanshu Kaushal, Sreelekshmy Mohandas, Sachin Daigude, M D Gokhale, Yash Joshi, Gajanan N. Sapkal, B. S. Sai Prasad, V.K. Srinivas, Shreekant Baradkar, Balram Bhargava, Gaurav Bhati, Annasaheb Suryawanshi, Gururaj Rao Deshpande, Siddhanath Metkari, Deepak Y. Patil, Dilip R. Patil, Pragya D Yadav, Savita Patil, Sanjay Gopale, Krishna Mohan Vadrevu, Basavaraj Mathapati, Kshitij Agarwal, Anita M. Shete, Sidharam Fulari, Hitesh Dighe, Triparna Majumdar, Kaumudi Kalele, Krishna Murthy Ella, Nivedita Gupta, Sharda Sharma, Abhimanyu Kumar, Dimpal A Nyayanit, Samiran Panda, Raman R. Gangakhedkar, and Chandrashekhar Mote
- Subjects
Male ,0301 basic medicine ,COVID-19 Vaccines ,viruses ,Science ,General Physics and Astronomy ,Enzyme-Linked Immunosorbent Assay ,02 engineering and technology ,Antibodies, Viral ,Placebo ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,medicine ,Animals ,Lymphocytes ,skin and connective tissue diseases ,Neutralizing antibody ,Inactivated vaccines ,Multidisciplinary ,medicine.diagnostic_test ,biology ,SARS-CoV-2 ,business.industry ,Immunogenicity ,fungi ,Pneumonia ,General Chemistry ,021001 nanoscience & nanotechnology ,medicine.disease ,Antibodies, Neutralizing ,Immunohistochemistry ,Macaca mulatta ,respiratory tract diseases ,body regions ,Titer ,030104 developmental biology ,Bronchoalveolar lavage ,Viral infection ,Preclinical research ,Nasal Swab ,Immunology ,biology.protein ,Female ,Antibody ,0210 nano-technology ,business - Abstract
The COVID-19 pandemic is a global health crisis that poses a great challenge to the public health system of affected countries. Safe and effective vaccines are needed to overcome this crisis. Here, we develop and assess the protective efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine in rhesus macaques. Twenty macaques were divided into four groups of five animals each. One group was administered a placebo, while three groups were immunized with three different vaccine candidates of BBV152 at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 fourteen days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralizing antibody titers from 3rd-week post-immunization. Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which exhibited interstitial pneumonia and localization of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry. This vaccine candidate BBV152 has completed Phase I/II (NCT04471519) clinical trials in India and is presently in phase III, data of this study substantiates the immunogenicity and protective efficacy of the vaccine candidates., SARS-CoV-2 vaccines are needed to fight the pandemic. Here, authors show protective efficacy and immunogenicity of the inactivated SARS-CoV-2 vaccine BBV152 in rhesus macaques. This vaccine is currently in clinical development.
- Published
- 2021
- Full Text
- View/download PDF